Medicine and Dentistry
Placebo
100%
Patient
50%
Therapeutic Procedure
25%
Hazard Ratio
18%
Creatinine
18%
Inpatient
18%
Amaurosis
18%
Maturity Onset Diabetes of the Young
12%
Chronic Kidney Disease
12%
Urine
12%
Patient with Type 2 Diabetes
12%
Albumin
12%
Glomerular Filtration Rate
12%
End Stage Renal Disease
12%
Fluid Retention
12%
Endothelin Receptor Antagonist
12%
Serum
6%
Adverse Event
6%
Follow up
6%
Low Drug Dose
6%
Renal Failure
6%
Heart Failure
6%
Patient with Diabetes
6%
Anemia
6%
Intention-to-Treat Analysis
6%
Kidney Transplantation
6%
Kidney Function
6%
Body Surface
6%
Albuminuria
6%
Short Course Therapy
6%
Adult
6%
Hospital
6%
Pharmacology, Toxicology and Pharmaceutical Science
Atrasentan
68%
Creatinine
18%
Blindness
18%
Non Insulin Dependent Diabetes Mellitus
12%
Albumin
12%
Chronic Kidney Failure
12%
End Stage Renal Disease
12%
Endothelin Receptor Antagonist
12%
Adverse Event
6%
Dialysis
6%
Heart Failure
6%
Anemia
6%
Albuminuria
6%
Kidney Failure
6%
Death
6%
Endothelin A Receptor Antagonist
6%